Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Research & Development (2020 - 2021)

Design Therapeutics' Research & Development history spans 2 years, with the latest figure at $7.3 million for Q4 2021.

  • For Q4 2021, Research & Development rose 170.94% year-over-year to $7.3 million; the TTM value through Dec 2021 reached $24.8 million, up 308.88%, while the annual FY2025 figure was $59.1 million, 33.32% up from the prior year.
  • Research & Development for Q4 2021 was $7.3 million at Design Therapeutics, down from $8.5 million in the prior quarter.
  • Across five years, Research & Development topped out at $8.5 million in Q3 2021 and bottomed at $377000.0 in Q1 2020.